AU672449B2 - Process for production of cell cultures with elevated content of endogenous cytokines - Google Patents
Process for production of cell cultures with elevated content of endogenous cytokines Download PDFInfo
- Publication number
- AU672449B2 AU672449B2 AU52790/93A AU5279093A AU672449B2 AU 672449 B2 AU672449 B2 AU 672449B2 AU 52790/93 A AU52790/93 A AU 52790/93A AU 5279093 A AU5279093 A AU 5279093A AU 672449 B2 AU672449 B2 AU 672449B2
- Authority
- AU
- Australia
- Prior art keywords
- lysates
- blood
- cultures
- cell
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000008569 process Effects 0.000 title claims abstract description 20
- 238000004113 cell culture Methods 0.000 title claims abstract description 16
- 102000004127 Cytokines Human genes 0.000 title claims description 25
- 108090000695 Cytokines Proteins 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 239000006166 lysate Substances 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 210000002700 urine Anatomy 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 238000005949 ozonolysis reaction Methods 0.000 claims abstract description 5
- 239000000021 stimulant Substances 0.000 claims abstract description 5
- 230000017854 proteolysis Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 14
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 238000009640 blood culture Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 241000501458 Cultus Species 0.000 claims 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 101100165798 Arabidopsis thaliana CYP86A1 gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000031055 positive regulation of mitosis Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The process entails exposing cultures of patient's autologous blood to an ozone/oxygen mixture and fractionating. The cell cultures are cultivated in a manner known per se and lysates are added as stimulants. The lysates are obtained by ozonolysis and proteolysis of blood or blood fractions and/or urine.
Description
p.-
SW,
d
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION For a Standard Patent
ORIGINAL
TO BE COMPLETED BY APPLICANT Name of Applicant: Actual inventor: Address for Service: HORST KIEF HORST KIEF 4 44,4 4,44 44 *4 4 #9 44,.
4 4. 4 44 4, *4 44 4 i.e 44 44 44 4 ~4.
4 4' *4 4 44 4 444444 4 S 4 44 WRAY ASSOCIATES, Primary Industry Terrace, Perth, Western Australia, 6000.
House, 239 Adelaide Attorney code: WR Invention Title: "Process, for Production of Cell Cultures with Elevated Content of Endogenous Cytokines" I roinJ The following statement is a full description invention, including the best method of performing it us:of this known to -2- THIS INVENTION relates to a process for the production of cell cultures with an elevated content of endogenous cytokines.
Cytokines are maeawgatr subntaneon that relay signals between lzmunocompetent cells and either cause the recipient ceall to assume certain functions and/or stimulate it to divide. The increased growth of certain immuanocompetent cell types in the blood should be considered the most important task of cytokines. At present, there is only one way of producing cytokines in rather large amounts at a reasonable market price; gone technology. Although the technology has matured and mass production is now under way, the process is no expensive that the cytokinos are presently among the most costly medications on the m rket. Although their structure is known and they can be produced in basically pure form, the use of cytokines still involves serious side effects.
Moreover, the administration of cytokines produced bY gone technology shown that, no matter how pure the production, foreign reactions still cannot be avoided, as in shown by the sometimes high rate of side oeffects of the res.pective products on the market. Furthermore, these suffer from one fundamental disadvantage; since they usually have a single cell type or group as the target cells and do not make use of the remainder of the immune system, the effeativeness of 4144 cytokines that are technologically produced and individually administered is not physiologically natural.
3. 0 In one form the invention resides in a process for the production of cell cultures with increajed content of ondogenous cytokines, comprising treating a patient's own blood cultures with an ozone-oxygen mixture and fractionation, wherein the cell cultures are cultivated in usual fashion and lysates are added as stimulants, the lysates having been obtained by ozonolysis and ft fractionation from blood or blood fractions and/or urine.
ft. 1A t.
-3- The process of the invention makes it possible to obtain endogenous cytokines which, because of their origin, once incorporated again in their own organism, are much more tolerable, and since they are left in the body's ewn medium, neither do they exhibit the above-mentioned defet of unphysiological action.
The possibility of producing immunomodulatory substances was first set forth in EP No. 0 265 548 Bl. There, lysates were obtained after deaggregation, by ozonolysis and proteolysise from individual blood fractions, as well as urine. Since then, the clinical effectiveness of these in autoimmune diseases has been established. This patent already describes the exposure of cell cultures to ozone gas and the use of the resulting lysates as immunomoculatory substances. Meanwhile (1990), the production of gamma-interferon from leukocyte cultures exposed to ozone gas has been demonstrated by Bocci. Bocci was also able to show that the information of Kief 20 regarding the concentration of 02/03 mixture ensures an optimal yield of gamma-interferon from whole blood ecultures. As can be seen from this work, the maximum yield in this procedure amounts to roughly 140 picograms per milliliter. If one uses whole blood or other fractions, such as leukocytes and lymphocytes together for a shortterm culture, it is also possible to obtain other cytokines .il. by EP No. 0 265 548 Bl, such as interleukin 2, which is present at 40 times more than the initial values in the I supernatant solution (the layer of nutrient solution VO x -4 I I2 -4 located above the calls that sink onto the bottom of the culture vessel) of such d culture, processed according to this technique. But in the process of the invention, much higher yields can be obtained, and various cytokine S mixtures can also be produced. Thus, the pro-mss of the invention starts with use of the process according to EP No. 0 265 548 B1. Its advanta is that it uses the lysates obtained by EP No. 0265 548 El for stimulation of mitosis in leukocyte and lymphocyte cultures that are first treated according to EP No. 0265 548 El. According to this technique, a variable spectrum of cytokines can be produced, depending on the choice of lysates obtained from serum, leukocytes, lymphocytes, erythrocytes and/or urine.
The primary procedure of the process for production of endogenous cytokines is as follows: First, whole blood is ozonized and incubated. After this, one obtains leukocytes by extraction of the buffycoat or lymphocytes by means of separating agents and zone centrifugation. These populations have already experienced 20 a selection through the buildup of oxygen radicals in the whole blood, since radical-sensitive cells are destroyed during this treatment and only the resistant cells survive.
These surviving cells are then cultivated in the usual way and lysates are added as stimulants. These lysates may be obtained, for example, from erythrocytes, granulocytes, or lymphocytes alone, or also from serum of the patient according to EP No. 0265 548 El.
A major advantage of the invented process is the exclusive use of endogenous material. This becomes very evident when compared with the usual nutrient solutions that are employed in liquid cell cultures and that almost always 4 4 .9*4 *4 *4 4, 4 4 4* 4 44 *4 4.
*4 4 *44 *4 .4 4 4 *444 4 44 44 4 *4 4 4.
44 4 4 .j :i i.l I 4 I t* 5 contain calf serum. The method according to the invention precludes a sensitization to animal protein or transmission of animal-borne disease.
Depending on the choice of the starting material, different cytokine mixtures can be induced; for example, when using a lysate obtained from serum according to EP No. 0265 548 B1, an especially abundant amount of gamma-interferon and interleukin 2 is obtained. After this, the cell cultures are lysed in the way already described by EP No. 0265 548 B1 and an injectable solution is prepared according to pharmaceutical procedures. Such lysates, even in dilutions of 1:1,000,000 and administered subcutaneously in amounts of 0.1 ml, induce an endogenous production of gammainterferon in the organism itself, which at first screening are found to be seven times higher than the starting value.
The interleukin 2 levels were on average six times above the norm. On the other hand, the soluble IL-2 receptors can be reduced to h to 1/3 in the first-described technique, which is an important criterion in the treatment 20 of autoimmune diseases.
A further increase is possible when blood stimulated in this way is again cultivated in usual fashion and exposed to lysates obtained according to EP No. 0265 548 Bl, which is a kind of culture cascade with even higher cytokine levels. The use of the lysates obtained per EP No. 0265 548 B1 as a stimulant for endogenous blood cultures, however, not only results in specific cytokines according to the choice of lysate and culture cell, but also increased budding of macrophages and killer cells, which are suitable for special application in malignant diseases.
The ozone treatment of the blood cultures has the further advantage that malignant cells from the corresponding donor I Ir I$ I
I.
IIII
I
4* 4r *4r
I*
i *4 I. I
I
I. 44 I. i r* 4 ic 4*l I 4l
I
I
r 4 IL 'M M -6blood are selectively inhibited in their mitosis by ozone (cf. Sweet, Ming-Shien Kao, Song-Chien, D Lee, Science Vol 209, 932), or even selectively destroyed, given an appropriate dose and overall mass. The special expense that is required in the preparation of endogenous stem cell cultures from the blood of cytostatically treated cancer patients is largely eliminated thanks to the ozone treatment. Urine contains, besides alpha 2 glycoprotein, transferrin, hemosiderin, immunoglobulin A and immunoplobulin G. Furthermore, it is possible to detect varying amounts of chains or chain fragments of immunoglobulins, in addition to ceruloplasmin, haptoglobulin solution fragments, and traces of alpha 2 macroglobulin. These components are an expression of both passive and active filtration of the kidneys. Thus, urine or even a protein mixture that has been concentrated according to the state of the art presents a possibility of stimulation of such cells, which could hardly be selected from the blood by laboratory techniques. This is shown by 20 the content of cytokines that can be detected spontaneously in the urine, and also when kidney disease is present (cf.
S. Sweet, Ming-Shien Kao, Song-Chien D. Lee, Science, Vol.
209 932).
If urine is processed according to EP No. 0265 548 B1 and 25 added as antigen to such a culture, the yield of interleukins 3, 4, 5 and 6 is substantially increased, Swhile at the same time the harvest of eosinophils is much I larger in number.
One can easily see that endogenous cytokines produced in 30 this way are much cheaper, along with the above mentioned advantage that the endogenous substances offer by virtue of their tolerance. It is not even necessary to prepare the cytokines in pure form, since the interplay of cytokine mixtures, endogenous proteins of the culture medium, cell nucleotides, and plasma component evidently exert a stronger, immunomodulatory effect than the cytokine alone.
11
Claims (9)
1. A process for the production of cell cultures with Increased content of endogenous cytokines comprising treating a patient's blood cultures with an ozone-oxygen mixture and fractionatlon, wherein the cell cultures are cultivated in usual fashion and lysates are added as stimulants, the lysates having been obtained by ozonolysis and fractionatlon from blood or blood fractions and/or urine.
2. A process according to claim 1 wherein repeated doses of lysates are added to the cell cultures.
3. A process according to claim 2 wherein one further dose of lysates is added to the cell culture.
4. A process according to any one of the preceding claims wherein the lysates *are obtained from serum. t
5. A process according to any one of the preceding claims wherein the cell 15 cultures are whole blood, leukocyte, lymphocyte, or mixed cultures. so S6. A process according to claim 1 substantially as herein described,
7. A lysate obtained from the cell culture obtained from the process according I to any one of the preceding claims.
8. A pharmaceutical preparation comprising a lysate of claim 7 and a S 20 p;harmaceutically acceptable carrier. Ri 'i a I iL u i_.
9. A process for Influencing the Immune system of a recipient comprising administering to the recipient an effective amount of the pharmaceutical preparation of claim 3. Dated this Seventh day of August 1996. DR HORST KIEF Applicant Wray Associates Perth, Western Australia Patent Attorneys for the Applicant ftftfftftJ ft ft ,IftA
111.1W 1-1 ABSTRACT Process for production of cell cultures with increased content of endogenous cytokines, by treatment of the patient's own blood cultures with an ozone-oxygen mixture .and fractionation, wherein the cell cultu,,res are cultivated in usual fashion and lysates are added as stimulants, the lysates having been obtained by ozonolysis and proteolysis from blood or blood fractions and/or urine. 044 0
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4244437.3 | 1992-12-29 | ||
DE4244437A DE4244437A1 (en) | 1992-12-29 | 1992-12-29 | Process for obtaining the body's own cytokines |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5279093A AU5279093A (en) | 1994-07-14 |
AU672449B2 true AU672449B2 (en) | 1996-10-03 |
Family
ID=6476762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52790/93A Ceased AU672449B2 (en) | 1992-12-29 | 1993-12-24 | Process for production of cell cultures with elevated content of endogenous cytokines |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0607593B1 (en) |
JP (1) | JPH0787965A (en) |
AT (1) | ATE196088T1 (en) |
AU (1) | AU672449B2 (en) |
CA (1) | CA2112314A1 (en) |
DE (2) | DE4244437A1 (en) |
ES (1) | ES2151895T3 (en) |
ZA (1) | ZA939718B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19903876B4 (en) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Process for the in vitro formation and accumulation of interleukin-1 receptor antagonists |
US6303154B1 (en) | 1999-09-24 | 2001-10-16 | Boris Breivogel | Chemical alteration of mammal urine and mammal blood |
ATE297745T1 (en) * | 2000-04-26 | 2005-07-15 | Boris Breivogel | CHEMICAL MODIFICATION OF MAMMAL URINE |
EP1555026A3 (en) * | 2000-04-26 | 2005-12-07 | Breivogel, Boris | Chemical modification of mammalian blood |
DE102006005016A1 (en) * | 2006-02-03 | 2007-08-16 | Orthogen Ag | Conditioned blood composition and process for its preparation |
EP2120975B1 (en) * | 2006-12-22 | 2015-09-23 | Horst Kief | Whole blood cultures comprising stimulated immune cells, and use thereof as medicaments |
EP2829278A1 (en) | 2013-07-23 | 2015-01-28 | Scientific BioTech GmbH | Serum for the treatment of diseases |
ITMI20131667A1 (en) * | 2013-10-09 | 2015-04-10 | Ind Paolo Gobbi Frattini | METHOD TO PRE-TREAT THE HEMATIC CELLS BEFORE SEPARATION. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8054887A (en) * | 1986-10-30 | 1988-05-05 | Horst Dr. Kief | An improved method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2015294A1 (en) * | 1989-04-28 | 1990-10-28 | John J. Rinehart | Generation and expansion of lak cells |
-
1992
- 1992-12-29 DE DE4244437A patent/DE4244437A1/en not_active Withdrawn
-
1993
- 1993-12-20 EP EP93120536A patent/EP0607593B1/en not_active Expired - Lifetime
- 1993-12-20 ES ES93120536T patent/ES2151895T3/en not_active Expired - Lifetime
- 1993-12-20 AT AT93120536T patent/ATE196088T1/en active
- 1993-12-20 DE DE59310100T patent/DE59310100D1/en not_active Expired - Fee Related
- 1993-12-23 CA CA002112314A patent/CA2112314A1/en not_active Abandoned
- 1993-12-24 AU AU52790/93A patent/AU672449B2/en not_active Ceased
- 1993-12-28 JP JP5352187A patent/JPH0787965A/en active Pending
- 1993-12-28 ZA ZA939718A patent/ZA939718B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8054887A (en) * | 1986-10-30 | 1988-05-05 | Horst Dr. Kief | An improved method |
Also Published As
Publication number | Publication date |
---|---|
EP0607593B1 (en) | 2000-09-06 |
EP0607593A2 (en) | 1994-07-27 |
JPH0787965A (en) | 1995-04-04 |
EP0607593A3 (en) | 1994-12-14 |
ZA939718B (en) | 1994-08-29 |
DE59310100D1 (en) | 2000-10-12 |
AU5279093A (en) | 1994-07-14 |
ES2151895T3 (en) | 2001-01-16 |
DE4244437A1 (en) | 1994-07-28 |
ATE196088T1 (en) | 2000-09-15 |
CA2112314A1 (en) | 1994-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Old | Tumor necrosis factor | |
Tomura et al. | A novel function of Vα14+ CD4+ NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system | |
Molina et al. | Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells | |
DE69520088T3 (en) | Interferon gamma-inducing polypeptide monoclonal antibody, and composition for interferon-gamma bound diseases | |
DE69132629T2 (en) | SURFACE COMPLEX FORMATION OF LYMPHOTOXIN | |
JPH04502151A (en) | Natural killer cell stimulating factor | |
JPH04506006A (en) | Human cytokine, interleukin-9 | |
Quesada et al. | Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients | |
Schink | Mistletoe therapy for human cancer: the role of the natural killer cells | |
AU672449B2 (en) | Process for production of cell cultures with elevated content of endogenous cytokines | |
JP2004307458A (en) | Galenical composition having anticancer/immune/hematopoietic function enhancing effect and oxidative living body damage suppressing effect and manufacturing method thereof | |
Prinz et al. | Allergen‐directed expression of Fc receptors for IgE (CD23) on human T lymphocytes is modulated by interleukin 4 and interferon‐γ | |
CA2186423C (en) | Protein which induces interferon-gamma production by immunocompetent cell | |
JPH09508116A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cytolytic activity | |
Welte et al. | Human interleukin 2: biochemistry, physiology, and possible pathogenetic role in immunodeficiency syndromes | |
AU632999B2 (en) | Method and means for immuno-stimulating blood treatment with a mitogen | |
EA015924B1 (en) | Treatment of hiv | |
EP0303687B1 (en) | Compositions for enhancing adcc therapy | |
US7196060B2 (en) | Method to enhance hematopoiesis | |
AU660493B2 (en) | Method for treatment of chronic lymphocytic leukemia using interleukin -6 | |
US5871725A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
Cazzola et al. | Update and future perspectives of a thymic biological response modifier (Thymomodulin) | |
WO1984004887A1 (en) | A METHOD OF TREATING INTERFERON SENSITIVE DISEASES, AND A METHOD AND A DEVICE FOR PREPARING A gamma-INTERFERON CONTAINING PREPARATION | |
Lakshmi Rao et al. | Administration of anti‐IL‐12 antibody in vivo inhibits rejection of a rat histiocytoma and suppresses cytokine response in a tumour‐bearing host | |
US4929443A (en) | Method of treating interferon sensitive diseases, and a method and device for preparing γ-interferon containing preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |